Dexpanthenol
Sources réglementaires consultées
Indications approuvées
- Carence en acide pantothénique chez l'adulte, notamment l'atonie intestinale postopératoire avec distension abdominale due à un retard de reprise de la motilité intestinale ou à un iléus paralytique, et le syndrome des pieds brûlants causé par une carence en vitamine B5.
Contre-indications
Absolues
- Hypersensibilité au dexpanthénol ou à l’un des excipients
- Iléus dû à une obstruction mécanique
Mises en garde cliniques
- Mise en garde majeure · Surveiller la résolution de l’hypomotilité gastro-intestinale. Utiliser avec une grande prudence en cas d’hémophilie, car le temps de saignement peut être prolongé. — https://cima.aemps.es/cima/dochtml/ft/17466/FT_17466.html
Interactions médicamenteuses
- ModéréeSuccinylcholine (chlorure de suxaméthonium)
Mécanisme: Le dexpanthénol peut prolonger l’effet myorelaxant.
Recommandation: Ne pas administrer de dexpanthénol dans l’heure suivant la succinylcholine.
https://cima.aemps.es/cima/dochtml/ft/17466/FT_17466.html
Effets indésirables
Communs (≥1%)
Fréquence non établie : réactions cutanées allergiques · Fréquence non établie : vomissements ou diarrhée · Fréquence non établie : réactions au site d'injection ou de perfusion
Grossesse et allaitement
Par mesure de précaution, il est préférable d’éviter l’utilisation pendant la grossesse. Pendant l’allaitement, décider d’interrompre l’allaitement ou le traitement après avoir évalué le bénéfice de l’allaitement pour l’enfant et celui du traitement pour la mère.
Bibliographie récente (PubMed)
Diaper dermatitis (DD) is a common inflammatory skin condition in the diaper area of infants, caused by a combination of host and environmental factors, such as moisture, friction, elevated skin pH, and prolonged exposure to urine and feces. This systematic review analyzed 13 studies involving 2,935 children to evaluate effective treatment and prevention strategies for DD. Key interventions identified include the use of disposable and emollient-containing diapers, gentle skincare practices (such as bathing every 1 to 2 days with mild cleansers and emollients), and pH-balanced wet wipes. Frequent diaper changes and allowing diaper-free time also help reduce skin irritation. Topical treatments, particularly emollients with zinc oxide or dexpanthenol, were found to be highly effective with minimal side effects. Preventive measures, such as using superabsorbent disposable diapers, regular application of barrier creams, and maintaining good hygiene, are crucial in reducing the incidence and severity of DD. In conclusion, a combined approach of proper diaper selection, gentle skincare, and judicious use of topical emollients is recommended for both treatment and prevention of DD in children.
Xerosis cutis (dry skin) is a common and burdensome symptom of atopic dermatitis (AD). Topical emollients restore skin hydration and barrier function through the physicochemical properties of their nonactive constituents (e.g., glycerol, urea, lactic acid, liquid paraffin, petrolatum) and represent the mainstay of basic therapy for xerosis cutis associated with AD. Newer "emollients plus" containing active ingredients may expand the treatment options available to patients with AD; however, we believe that basic emollients remain an important strategy for the long-term management of xerosis cutis. To that end, this article aims to review the clinical value of basic emollients for treating xerosis cutis in AD. We performed a series of literature searches to identify clinical studies of basic emollients containing one or more of the following ingredients: almond and coconut oils, amino acids, chondroitin, dexpanthenol, glucose, glycerol, glycosaminoglycans, hyaluronic acid, lactic acid, lanolin, olive oil, paraffin, petrolatum, phospholipids, polyunsaturated fatty acids, pyroglutamic acid, squalene, triglycerides, urea, vegetable oils, and vitamin E. From these searches, the authors identified articles of interest that described the efficacy of basic emollients for the treatment of xerosis cutis associated with AD. Studies included in our review varied widely in terms of sample size, study design, interventions, and endpoints but collectively showed that most basic emollient formulations are safe and effective at improving objective and subjective measures of xerosis cutis. These studies also demonstrated the importance of ongoing emollient therapy to avoid xerosis relapse and the additive benefits of emollients that combine ingredients with complementary biophysical properties (e.g., glycerol with its humectant effect plus petrolatum with its occludent effect). Overall, the current body of literature reinforces the role of basic emollients as effective and accessible
Issues of regeneration of the cornea, which is the most vulnerable structure of the eyeball, suffering from various diseases and injuries, burns, when wearing contact lenses and glaucoma, are highly relevant for ophthalmologists. It is also necessary to minimize damage and stimulate corneal epithelization during and after the use of steroidal and non-steroidal anti-inflammatory drugs, antibacterial drugs and antiseptics, which have a cytotoxic effect and often inhibit regeneration processes, potentially even leading to the development of corneal epithelial defects. This review analyzes the effectiveness of a promising drug 5% dexpanthenol in terms of improving the reparative processes and the function of epithelial cells. Вопросы регенерации роговицы как самой уязвимой структуры глазного яблока, страдающей при различных заболеваниях и травмах, ожогах, при ношении контактных линз и при глаукоме, весьма актуальны для офтальмологов. Также необходимыми являются минимизация повреждения и стимуляция эпителизации роговицы после применения стероидных и нестероидных противовоспалительных средств, антибактериальных препаратов и антисептических средств, оказывающих цитотоксический эффект и зачастую тормозящих процессы регенерации, вплоть до развития дефектов эпителия роговицы. Одним из изученных и перспективных средств является декспантенол 5%, оценке эффективности которого в отношении улучшения репаративных процессов и воздействию на функцию эпителиоцитов и посвящен данный обзор.
Nowadays, moisturizers contain non-steroidal anti-inflammatory agents that help for treatment of atopic dermatitis (AD). Defensil® (black currant seed oil, sunflower oil, and balloon vine), a new anti-inflammatory, obtained from plant extracts, remain had a few studies for AD. To compare the effectiveness of moisturizer containing 3% Defensil®, 5% dexpanthenol and ceramide (LDC) with 5% urea cream in childhood AD treatment. Thirty-eight patients with diagnosis of atopic dermatitis by UK working party's criteria were recruited in randomized, controlled, double-blinded 4-week study. The patients were received with twice-daily application of LDC cream on one side of the body and 5% urea cream on the opposite side. The clinical severity was assessed by modified scoring of atopic dermatitis (SCORAD). Median time to remission was analyzed by survival analysis. Thirty-seven out of 38 patients accomplished the protocol. The clinical SCORAD significantly improved from baseline in both groups (p < 0.001) after 2 and 4 weeks. Furthermore, the LDC group significantly reduced severity of disease better than the 5% urea group (P = 0.043). The mean difference SCORAD scores were -13.83 (±1.83) and -13.04 (±3.22) respectively. Stratum corneum hydration (SCH) was enhanced from baseline in both groups (p < 0.001) but no statistically significant difference between both groups. Median time to remission had no statistically significant difference (P = 0.697). The effectiveness of LDC cream is better than 5% urea cream for improving clinical atopic dermatitis. It was suggested that moisturizer containing LDC could be used for the treatment of mild-to-moderate childhood atopic dermatitis.
Atopic dermatitis (AD) is an inflammatory skin disease of multiple phenotypes and endotypes, and is highly prevalent in children. Many people of all ages, including active adolescents, pregnant women, and the elderly, suffer from AD, experiencing chronicity, flares, and unexpected relapse. Dexpanthenol has multiple pharmacological effects and has been employed to treat various skin disorders such as AD. We aimed to summarize the up-to-date evidence relating to dexpanthenol and to provide a consensus on how to use dexpanthenol effectively for the treatment of AD. The evidence to date on the application and efficacy of dexpanthenol in AD was reviewed. The literature search focused on dexpanthenol use and the improvement of skin barrier function, the prevention of acute flares, and its topical corticosteroid (TCS) sparing effects. Evidence and recommendations for special groups such as pregnant women, and the effects of dexpanthenol and emollient plus in maintenance therapy, were also summarized. Dexpanthenol is effective and well-tolerated for the treatment of AD. Dexpanthenol improves skin barrier function, reduces acute and frequent flares, has a significant TCS sparing effect, and enhances wound healing for skin lesions. This review article provides helpful advice for clinicians and patients on the proper maintenance treatment of AD. Dexpanthenol, as an active ingredient in ointments or emollients, is suitable for the treatment and maintenance of AD. This paper will guide dermatologists and clinicians to consider dexpanthenol as a treatment option for mild to moderate AD.